Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation is ‘n kutane toestand wat gekenmerk word deur verhoogde pigment in die vel na inflammasie. Postinflammatory hyperpigmentation kan veroorsaak word deur langdurige sonblootstelling, inflammasie of ander velbeserings, insluitend dié wat met aknee verband hou. Mense met donkerder velkleure is gewoonlik meer geneig tot hiperpigmentasie by oormatige sonblootstelling.
☆ AI Dermatology — Free Service
In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) is 'n gereelde velprobleem wat na velontsteking of besering voorkom. Dit hou lank en is erger by mense met donkerder velkleure (Fitzpatrick skin types III–VI). Alhoewel dit dikwels van self beter word, kan dit 'n rukkie neem; daarom is behandeling vir 'n lang tydperk nodig. Die kombinasie van verskillende behandelings werk die beste.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation is ’n algemene gevolg van velontsteking. Dit affekteer donkerder‑vel individue meer ernstig en gereeld. Studies toon dat kwessies soos postinflammatory hyperpigmentation een van die hoofredes is waarom mense met donkerder velkleure dermatologiese sorg soek. Vroeë behandeling is noodsaaklik om postinflammatory hyperpigmentation te beheer en begin gewoonlik met die bestuur van die aanvanklike inflammatoriese toestand. Die eerste behandelingslyn behels gewoonlik die gebruik van aktiewe middels wat die vel verlig, tesame met sonskerm vir beskerming. Hierdie middels, soos hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts, kan oormatige pigmentasie effektief verminder. Daarbenewens word retinoïde, mequinol, ascorbiese suur, niacinamide, N‑acetyl‑glucosamine en soja ook as depigmenterende middels gebruik, en nuwe behandelings kom voortdurend op. Terwyl aktuele behandelings gewoonlik effektief is vir oppervlakkige hiperpigmentasie, kan prosedures (laser, chemical peel) nodig wees vir hardnekkige gevalle. Dit is belangrik om versigtig te wees met hierdie behandelings om irritasie en verergering van postinflammatory hyperpigmentation te vermy.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
